Published in Stat Med on July 15, 1997
Effectiveness of a Well-being Web-based Intervention | NCT01586949
Principal stratification in causal inference. Biometrics (2002) 12.34
Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol (2010) 6.03
Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. PLoS Med (2007) 3.91
Surrogate measures and consistent surrogates. Biometrics (2013) 3.59
Prepregnancy dietary protein intake, major dietary protein sources, and the risk of gestational diabetes mellitus: a prospective cohort study. Diabetes Care (2013) 2.81
The intermediate endpoint effect in logistic and probit regression. Clin Trials (2007) 2.67
Trauma Exposure and Posttraumatic Stress Disorder Symptoms Predict Onset of Cardiovascular Events in Women. Circulation (2015) 2.44
Association between sleep and blood pressure in midlife: the CARDIA sleep study. Arch Intern Med (2009) 2.39
Covariate measurement error correction methods in mediation analysis with failure time data. Biometrics (2014) 2.10
Childhood gender nonconformity: a risk indicator for childhood abuse and posttraumatic stress in youth. Pediatrics (2012) 1.95
Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. Arch Intern Med (2012) 1.92
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Abuse in childhood and adolescence as a predictor of type 2 diabetes in adult women. Am J Prev Med (2010) 1.66
Roadway proximity and risk of sudden cardiac death in women. Circulation (2014) 1.52
Consumption of Meals Prepared at Home and Risk of Type 2 Diabetes: An Analysis of Two Prospective Cohort Studies. PLoS Med (2016) 1.43
Gender minority social stress in adolescence: disparities in adolescent bullying and substance use by gender identity. J Sex Res (2014) 1.42
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. Ann Appl Stat (2008) 1.41
Endometriosis and Risk of Coronary Heart Disease. Circ Cardiovasc Qual Outcomes (2016) 1.40
Comparing biomarkers as principal surrogate endpoints. Biometrics (2011) 1.39
Association between sleeping difficulty and type 2 diabetes in women. Diabetologia (2016) 1.38
Sexual-orientation disparities in cigarette smoking in a longitudinal cohort study of adolescents. Nicotine Tob Res (2012) 1.34
Physical and sexual abuse in childhood as predictors of early-onset cardiovascular events in women. Circulation (2012) 1.31
Gang exposure and pregnancy incidence among female adolescents in San Francisco: evidence for the need to integrate reproductive health with violence prevention efforts. Am J Epidemiol (2008) 1.30
Prepregnancy adherence to dietary patterns and lower risk of gestational diabetes mellitus. Am J Clin Nutr (2012) 1.29
The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetologia (2012) 1.28
Adolescent dairy product consumption and risk of type 2 diabetes in middle-aged women. Am J Clin Nutr (2011) 1.20
On assessing surrogacy in a single trial setting using a semicompeting risks paradigm. Biometrics (2009) 1.14
Elevated risk of posttraumatic stress in sexual minority youths: mediation by childhood abuse and gender nonconformity. Am J Public Health (2012) 1.14
Home endotoxin exposure and wheeze in infants: correction for bias due to exposure measurement error. Environ Health Perspect (2006) 1.12
Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics (2013) 1.08
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol (2009) 1.02
Associations between red meat intake and biomarkers of inflammation and glucose metabolism in women. Am J Clin Nutr (2013) 1.00
Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes (2012) 1.00
Posttraumatic stress disorder and incidence of type 2 diabetes mellitus in a sample of women: a 22-year longitudinal study. JAMA Psychiatry (2015) 1.00
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol (2013) 0.99
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc (2011) 0.98
Grasping nettles: cellular heterogeneity and other confounders in epigenome-wide association studies. Hum Mol Genet (2014) 0.97
Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma. Ophthalmology (2013) 0.97
The mediating effect of childhood abuse in sexual orientation disparities in tobacco and alcohol use during adolescence: results from the Nurses' Health Study II. Cancer Causes Control (2010) 0.97
Geomedicine: area-based socioeconomic measures for assessing risk of hospital reutilization among children admitted for asthma. Am J Public Health (2012) 0.96
Exceptional parental longevity associated with lower risk of Alzheimer's disease and memory decline. J Am Geriatr Soc (2010) 0.96
Role of adiposity and lifestyle in the relationship between family history of diabetes and 20-year incidence of type 2 diabetes in U.S. women. Diabetes Care (2010) 0.94
Association of maternal exposure to childhood abuse with elevated risk for autism in offspring. JAMA Psychiatry (2013) 0.93
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Res (2015) 0.92
Exposure to Greenness and Mortality in a Nationwide Prospective Cohort Study of Women. Environ Health Perspect (2016) 0.92
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92
Posttraumatic stress disorder across two generations: concordance and mechanisms in a population-based sample. Biol Psychiatry (2012) 0.91
Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. J Autism Dev Disord (2014) 0.91
Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol (2015) 0.89
Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother (2013) 0.87
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res (2014) 0.87
A priori-defined diet quality indexes and risk of type 2 diabetes: the Multiethnic Cohort. Diabetologia (2014) 0.85
Predicting treatment effects using biomarker data in a meta-analysis of clinical trials. Stat Med (2010) 0.85
Sugar-sweetened beverage consumption and age at menarche in a prospective study of US girls. Hum Reprod (2015) 0.85
Changes in Overall Diet Quality and Subsequent Type 2 Diabetes Risk: Three U.S. Prospective Cohorts. Diabetes Care (2016) 0.85
Population attributable fractions for late postnatal mother-to-child transmission of HIV-1 in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2010) 0.84
When is the difference method conservative for assessing mediation? Am J Epidemiol (2015) 0.83
Infertility and its treatments in association with autism spectrum disorders: a review and results from the CHARGE study. Int J Environ Res Public Health (2013) 0.83
Sexual orientation disparities in substance misuse: the role of childhood abuse and intimate partner violence among patients in care at an urban community health center. Subst Use Misuse (2013) 0.83
Phobic anxiety symptom scores and incidence of type 2 diabetes in US men and women. Brain Behav Immun (2013) 0.83
Inflammation as a Mediator of the Association Between Race and Atrial Fibrillation: Results from the Health, Aging, and Body Composition Study. JACC Clin Electrophysiol (2015) 0.82
Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models. Stat Biopharm Res (2010) 0.82
Birth weight and risk of type 2 diabetes in the black women's health study: does adult BMI play a mediating role? Diabetes Care (2014) 0.82
Peritoneal Equilibration Test and Patient Outcomes. Clin J Am Soc Nephrol (2015) 0.81
Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. PLoS One (2015) 0.81
The association of the QT interval with atrial fibrillation and stroke: the Multi-Ethnic Study of Atherosclerosis. Clin Res Cardiol (2015) 0.80
Masculine boys, feminine girls, and cancer risk behaviors: an 11-year longitudinal study. J Adolesc Health (2014) 0.80
Surrogate markers for time-varying treatments and outcomes. Clin Trials (2015) 0.80
Low Carbohydrate-Diet Scores and Long-term Risk of Type 2 Diabetes Among Women With a History of Gestational Diabetes Mellitus: A Prospective Cohort Study. Diabetes Care (2015) 0.80
Social Integration and Reduced Risk of Coronary Heart Disease in Women: The Role of Lifestyle Behaviors. Circ Res (2017) 0.80
Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One (2015) 0.79
Genetic Investigation Into the Differential Risk of Atrial Fibrillation Among Black and White Individuals. JAMA Cardiol (2016) 0.79
Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study. PLoS One (2012) 0.79
Parental smoking in pregnancy and the risks of adult-onset hypertension. Hypertension (2012) 0.78
Physical activity and risk of endometrial adenocarcinoma in the Nurses' Health Study. Int J Cancer (2013) 0.78
Linear Growth Faltering Among HIV-Exposed Uninfected Children. J Acquir Immune Defic Syndr (2016) 0.77
Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med (2015) 0.77
Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol (2015) 0.77
Some extensions in continuous models for immunological correlates of protection. BMC Med Res Methodol (2015) 0.77
Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol (2016) 0.77
Sunburn, sun exposure, and sun sensitivity in the Study of Nevi in Children. Ann Epidemiol (2015) 0.76
Association between alcohol consumption and plasma fetuin-A and its contribution to incident type 2 diabetes in women. Diabetologia (2013) 0.76
Extended duration therapy with transdermal nicotine may attenuate weight gain following smoking cessation. Addict Behav (2011) 0.76
Effect of multivitamin supplements on weight gain during pregnancy among HIV-negative women in Tanzania. Matern Child Nutr (2012) 0.75
A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey. For Immunopathol Dis Therap (2016) 0.75
Gender-modulated risk of coronary heart disease, diabetes and coronary mortality among Turks for three major risk factors, and residual adiposity risk. BMC Endocr Disord (2016) 0.75
Evaluating surrogate marker information using censored data. Stat Med (2017) 0.75
Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling. Lifetime Data Anal (2016) 0.75
Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. Front Immunol (2016) 0.75
Concurrent polysubstance use in a longitudinal study of US youth: associations with sexual orientation. Addiction (2016) 0.75
Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the Elderly Population. PLoS One (2016) 0.75
Psychological mediators related to clinical outcome in cognitive behavioural therapy for coronary heart disease: A sub-analysis from the SUPRIM trial. Eur J Prev Cardiol (2017) 0.75
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol (2017) 0.75
Mammographic density and breast cancer risk: a mediation analysis. Breast Cancer Res (2016) 0.75
Preterm Delivery and Maternal Cardiovascular Disease in Young and Middle-Aged Adult Women. Circulation (2017) 0.75
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol (2017) 0.75
Food quality score and the risk of coronary artery disease: a prospective analysis in 3 cohorts. Am J Clin Nutr (2016) 0.75
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA (1992) 6.99
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med (1997) 6.12
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (1989) 3.83
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Designs for group sequential tests. Control Clin Trials (1984) 3.56
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Estimating medical costs from incomplete follow-up data. Biometrics (1997) 3.25
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics (1989) 2.51
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol (1982) 2.12
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Estimation of HIV dynamic parameters. Stat Med (1998) 1.85
Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis (1999) 1.58
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol (1993) 1.52
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
Incubation periods for paediatric AIDS patients. Nature (1988) 1.47
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med (1982) 1.47
AIDS: has the problem been adequately assessed? Rev Infect Dis (1986) 1.45
Policies for study monitoring and interim reporting of results. J Clin Oncol (1987) 1.41
Design considerations for AIDS trials. N Engl J Med (1990) 1.38
Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer (1979) 1.34
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol (1985) 1.29
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol (1995) 1.23
An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis (1997) 1.17
Symmetric group sequential test designs. Biometrics (1989) 1.13
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis (2001) 1.12
Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials (1984) 1.05
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler (2008) 1.04
Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med (1985) 1.01
Group sequential designs for monitoring survival probabilities. Biometrics (1996) 0.98
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer (1994) 0.97
Interim analyses in clinical trials. Oncology (Williston Park) (1990) 0.96
Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology (1989) 0.95
Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol (1984) 0.93
Performing serial testing of treatment effects. Experientia Suppl (1982) 0.90
Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep (1979) 0.89
Evaluation of response criteria in advanced lung cancer. Cancer (1979) 0.89
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer (1993) 0.87
The conditional latency distribution of AIDS for persons infected by blood transfusion. J Acquir Immune Defic Syndr (1989) 0.86
Statistical issues in the design of HIV vaccine trials. Annu Rev Public Health (1995) 0.86
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol (1987) 0.86
Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep (1985) 0.85
Treatment of HIV infection--progress in perspective. N Engl J Med (1992) 0.84
Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J Urol (1984) 0.83
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer (1995) 0.82
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials (1995) 0.82
Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Cancer Treat Rep (1987) 0.81
Design, conduct, and analysis of clinical trials in disease due to methicillin-resistant Staphylococcus aureus. Clin Pharmacol Ther (2009) 0.80
Strategies for cohort sampling under the Cox proportional hazards model, application to an AIDS clinical trial. Lifetime Data Anal (1999) 0.80
Single metastasis to the brain. Surgical treatment in 122 consecutive patients. Mayo Clin Proc (1981) 0.80
Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS (1999) 0.80
An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. Cancer Clin Trials (1981) 0.80
A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. Cancer Treat Rep (1980) 0.79
Definitive radiation therapy for prostatic carcinoma: Mayo clinic experience. J Urol (1980) 0.78
Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group study. Invest New Drugs (1994) 0.78
Surgical adjuvant therapy of rectal cancer. Semin Oncol (1988) 0.78
Historical controls, data banks, and randomized trials in clinical research: a review. Cancer Treat Rep (1982) 0.78
Regression analysis of censored and truncated data: estimating reporting-delay distributions and AIDS incidence from surveillance data. Biometrics (1994) 0.77
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study. Invest New Drugs (1991) 0.77
Dianhydrogalactitol and radiation therapy. Treatment of supratentorial glioma. JAMA (1979) 0.77
Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. J Urol (1983) 0.77
Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: a Southwest Oncology Group Pilot study. Int J Radiat Oncol Biol Phys (1995) 0.77
Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate (1983) 0.77
Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer (1981) 0.76
Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. Invest New Drugs (1991) 0.76
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol (1992) 0.76
Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung. Int J Radiat Oncol Biol Phys (1979) 0.76
Effects on overviews of early stopping rules for clinical trials. Stat Med (1987) 0.76
Viral load and response to treatment of HIV. N Engl J Med (1996) 0.75
VM-26 in colorectal carcinoma: a Southwest Oncology Group study. Invest New Drugs (1990) 0.75
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study. Invest New Drugs (1990) 0.75
Risk of local urethral recurrence after radical cystectomy for bladder cancer. J Urol (1984) 0.75
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. J Clin Oncol (1985) 0.75
Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study. Cancer Treat Rep (1987) 0.75
Guidelines for the reporting of clinical trials. Semin Oncol (1988) 0.75
Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. J Biol Response Mod (1990) 0.75
Phase II evaluation of triazinate in patients with metastatic lung cancer. Cancer Treat Rep (1981) 0.75
Phase II evaluation of PALA in patients with metastatic lung cancer. Cancer Treat Rep (1981) 0.75
Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study. Cancer Treat Rep (1987) 0.75
Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712. Invest New Drugs (1993) 0.75
Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer. Cancer (1981) 0.75
Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study. Cancer Treat Rep (1987) 0.75
Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys (1980) 0.75
Phase II evaluation of maytansine in patients with advanced head and neck cancer. Cancer Treat Rep (1980) 0.75
Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer (1981) 0.75
VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung. Tumori (1979) 0.75
Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study. Cancer Treat Rep (1984) 0.75
Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma. Cancer Treat Rep (1980) 0.75